These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 35443108)
21. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial. Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540 [TBL] [Abstract][Full Text] [Related]
22. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with Bewersdorf JP; Patel KK; Goshua G; Shallis RM; Podoltsev NA; Stahl M; Stein EM; Huntington SF; Zeidan AM Leuk Lymphoma; 2023 Feb; 64(2):454-461. PubMed ID: 36493798 [TBL] [Abstract][Full Text] [Related]
24. Clinical development of IDH1 inhibitors for cancer therapy. Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243 [TBL] [Abstract][Full Text] [Related]
25. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803 [TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873 [TBL] [Abstract][Full Text] [Related]
27. Is Induction of Hypomethylation with Ivosidenib and 5-Azacitidine Curative Regimen against IDH1-Mutated Acute Myeloid Leukemia? Takahashi K Anticancer Agents Med Chem; 2023; 23(8):864-866. PubMed ID: 36503457 [No Abstract] [Full Text] [Related]
28. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Fathi AT; Kim HT; Soiffer RJ; Levis MJ; Li S; Kim AS; DeFilipp Z; El-Jawahri A; McAfee SL; Brunner AM; Amrein PC; Mims AS; Knight LW; Kelley D; Bottoms AS; Perry LH; Wahl JL; Brock J; Breton E; Marchione DM; Ho VT; Chen YB Clin Cancer Res; 2023 Jun; 29(11):2034-2042. PubMed ID: 37014667 [TBL] [Abstract][Full Text] [Related]
29. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia. Cortes JE Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392 [TBL] [Abstract][Full Text] [Related]
30. Ivosidenib Boosts OS with Azacitidine in AML. Cancer Discov; 2022 Jul; 12(7):1602-1603. PubMed ID: 35532213 [TBL] [Abstract][Full Text] [Related]
31. Ivosidenib: First Global Approval. Dhillon S Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701 [TBL] [Abstract][Full Text] [Related]
32. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML; Sallman DA; Hossain M; Marchione DM; Bai X; Patel PA; Kapsalis SM; Garcia-Manero G; Fathi AT Blood Adv; 2024 Aug; 8(15):4209-4220. PubMed ID: 38640348 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia. Fan B; Chen Y; Yin F; Hua L; Almon C; Nabhan S; Cooper M; Yang H; Hossain M Clin Pharmacol Drug Dev; 2022 Apr; 11(4):429-441. PubMed ID: 35166065 [TBL] [Abstract][Full Text] [Related]
34. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251 [TBL] [Abstract][Full Text] [Related]
35. A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. Lachowiez CA; Loghavi S; Zeng Z; Tanaka T; Kim YJ; Uryu H; Turkalj S; Jakobsen NA; Luskin MR; Duose DY; Tidwell RSS; Short NJ; Borthakur G; Kadia TM; Masarova L; Tippett GD; Bose P; Jabbour EJ; Ravandi F; Daver NG; Garcia-Manero G; Kantarjian H; Garcia JS; Vyas P; Takahashi K; Konopleva M; DiNardo CD Blood Cancer Discov; 2023 Jul; 4(4):276-293. PubMed ID: 37102976 [TBL] [Abstract][Full Text] [Related]
36. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Garcia-Manero G; Abaza Y; Takahashi K; Medeiros BC; Arellano M; Khaled SK; Patnaik M; Odenike O; Sayar H; Tummala M; Patel P; Maness-Harris L; Stuart R; Traer E; Karamlou K; Yacoub A; Ghalie R; Giorgino R; Atallah E Blood Adv; 2019 Feb; 3(4):508-518. PubMed ID: 30760466 [TBL] [Abstract][Full Text] [Related]
37. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia. Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972 [TBL] [Abstract][Full Text] [Related]
39. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study. Pabst T; Papayannidis C; Demirkan F; Doronin V; Fogliatto LM; Guttke C; Gyan E; Hamad N; Herrera P; Hultberg A; Jacobs J; Johnson AJ; Langlois A; Ma X; Martinelli G; Arnan M; Müller R; Nottage K; Ofran Y; Özcan M; Samoilova O; Tolbert JA; Trudel GC; Xiu L; Vey N; Wei AH Lancet Haematol; 2023 Nov; 10(11):e902-e912. PubMed ID: 37914483 [TBL] [Abstract][Full Text] [Related]
40. Ivosidenib in Isocitrate Dehydrogenase 1 Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]